Development and Evaluation of [ 68 Ga]Ga-FAPI-A1 as a Novel Radiotracer Targeting Fibroblast Activation Protein
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.5c01307 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Shijun Xiang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha 410008, China. Hauptthemen laut MEDLINE: Gallium Radioisotopes, Radiopharmaceuticals, Membrane Proteins, Gelatinases. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Science and Technology Program of Hunan Province, National Natural Science Foundation of China, Ministry of Industry and Information Technology of China.
Abstract (Originalsprache)
Radiolabeled fibroblast activation protein inhibitors (FAPIs) have limited clinical translation potential due to suboptimal tumor retention. In this study, we engineered novel polymeric FAPI tracers to enhance molecular affinity, tumor uptake, and retention. These tracers were comprehensively evaluated for their binding specificity, biodistribution characteristics, and potential applications in both preclinical PET/CT imaging and preliminary clinical studies involving human volunteers, which revealed that the 68Ga radiolabeling of polymerized FAPIs enhanced all three parameters. For therapeutic evaluation, we compared the tumor growth inhibition effects of [177Lu]Lu-FAPI-A1 and [177Lu]Lu-FAPI-46. FAPI-A1 exhibited a high FAP affinity and specificity. In HT-1080-FAP tumor models, [68Ga]Ga-FAPI-A1 demonstrated significantly higher tumor uptake, longer retention, and slower clearance compared to [68Ga]Ga-FAPI-46. [177Lu]Lu-FAPI-A1 induced a significant tumor growth suppression. Clinical uptake of [68Ga]Ga-FAPI-A1 mirrored that of FAPI-46. FAPI-A1 exhibits enhanced binding affinity, which improves tumor uptake and prolongs the retention of [177Lu]Lu-FAPI-A1, supporting its theranostic potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha 410008, China.
- Department of Nuclear Medicine, Weifang People's Hospital, Shandong Second Medical University, Weifang 261041, Shandong Province, China.
- National Clinical Research Center for Geriatric Disorders (Xiangya), Changsha 410008, China.
- Key Laboratory of Biological Nanotechnology of National Health Commission, Xiangya Hospital, Central South University, Changsha 410008, China.
ORCID-Profile: Shuo Hu
Förderung
- Science and Technology Program of Hunan Province
- National Natural Science Foundation of China
- Ministry of Industry and Information Technology of China
- National Clinical Research Center for Geriatric Diseases (XIANGYA)
Zitieren
APA
Xiang, S., Zhou, M., Tang, Y., Xu, P., Li, J., & Hu, S. (2026). Development and Evaluation of [ 68 Ga]Ga-FAPI-A1 as a Novel Radiotracer Targeting Fibroblast Activation Protein. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01307
Vancouver
Xiang S, Zhou M, Tang Y, Xu P, Li J, Hu S. Development and Evaluation of [ 68 Ga]Ga-FAPI-A1 as a Novel Radiotracer Targeting Fibroblast Activation Protein. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01307
BibTeX
@article{Xiang2026,
author = {Xiang, Shijun and Zhou, Ming and Tang, Yongxiang and Xu, Pengfei and Li, Jian and Hu, Shuo},
title = {Development and Evaluation of [ 68 Ga]Ga-FAPI-A1 as a Novel Radiotracer Targeting Fibroblast Activation Protein},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.5c01307}
}
EUVIMED